BioLineRX Ltd (BLRX) Stock Price

BLRXStock

$2.60+136.20%52W

Market Cap$11.36M

P/E—

PEG Ratio—

Div yield—

Beta0.64

BLRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.43%

Price vs S&P 500 (4W)-1.54%

VGM Score38.49

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)7.66x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.00

Price vs S&P 500 (YTD)-24.17%

Gross Margin (TTM)80.51%

Net Profit Margin (TTM)-171.44%

EPS (TTM)$-0.00

10-Day Avg Trading Volume2.98M

EPS Excl Extra (TTM)$-0.00

EPS (Annual)$-0.00

ROI (Annual)-7.15%

Gross Margin (Annual)80.51%

Net Profit Margin (5Y Avg)-311.21%

Cash / Share (Quarterly)$0.01

Revenue Growth QoQ (YoY)-98.35%

ROA (Last FY)-4.95%

Revenue Growth TTM (YoY)-95.92%

EBITD / Share (TTM)$-0.00

ROE (5Y Avg)-125.37%

Operating Margin (TTM)-871.69%

Cash Flow / Share (Annual)$-0.00

P/B Ratio0.72x

P/B Ratio (Quarterly)0.77x

Net Income / Employee (Annual)$-84,400

EV / Revenue (TTM)17.02x

Net Interest Coverage (TTM)-0.28x

ROA (TTM)-4.82%

EV / EBITDA (TTM)2.36x

EPS Incl Extra (Annual)$-0.00

Current Ratio (Annual)1.95x

Quick Ratio (Quarterly)1.76x

3-Month Avg Trading Volume4.91M

52-Week Price Return136.20%

Revenue / Employee (TTM)$49,200

Tangible BV / Share (Quarterly)$0.00

P/S Ratio (Annual)11.17x

Asset Turnover (Annual)0.03x

52-Week High$2.40

Operating Margin (5Y Avg)-413.00%

EPS Excl Extra (Annual)$-0.00

CapEx CAGR (5Y)-5.85%

Tangible BV CAGR (5Y)-30.76%

26-Week Price Return-12.50%

Quick Ratio (Annual)1.76x

13-Week Price Return-12.50%

Total Debt / Equity (Annual)0.56x

Current Ratio (Quarterly)1.95x

Enterprise Value$20.08M

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)-35.58%

Revenue / Employee (Annual)$49,200

Pretax Margin (Annual)-171.69%

Cash / Share (Annual)$0.01

3-Month Return Std Dev91.62%

Gross Margin (5Y Avg)62.71%

Net Income / Employee (TTM)$-84,300

ROE (Last FY)-11.13%

Net Interest Coverage (Annual)0.52x

EPS Basic Excl Extra (Annual)$-0.00

Receivables Turnover (TTM)0.94x

Total Debt / Equity (Quarterly)0.56x

EPS Incl Extra (TTM)$-0.00

ROI (TTM)-6.38%

P/S Ratio (TTM)11.17x

Pretax Margin (5Y Avg)-311.21%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.00

Price vs S&P 500 (52W)149.95%

Year-to-Date Return-12.50%

5-Day Price Return-6.67%

EPS Normalized (Annual)$-0.00

ROA (5Y Avg)-37.88%

Net Profit Margin (Annual)-171.69%

Month-to-Date Return-12.50%

Cash Flow / Share (TTM)$-0.18

EBITD / Share (Annual)$-0.00

Operating Margin (Annual)-871.78%

LT Debt / Equity (Annual)0.25x

ROI (5Y Avg)-72.09%

LT Debt / Equity (Quarterly)0.25x

EPS Basic Excl Extra (TTM)$-0.00

P/TBV (Quarterly)7.66x

P/B Ratio (Annual)0.77x

Inventory Turnover (TTM)0.09x

Pretax Margin (TTM)-171.44%

Book Value / Share (Annual)$0.01

Price vs S&P 500 (13W)-14.45%

Beta0.64x

P/FCF (Annual)1.28x

Revenue / Share (TTM)$0.00

ROE (TTM)-10.27%

52-Week Low$1.10

vGradeB

gGradeF

mGradeC

vgmGradeD

BLRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 27, 2026	-$1.04	$0.00	+100.00%(+$1.04)
Q4 2025	Mar 23, 2026	-$0.77	$0.00	+100.00%(+$0.77)
Q3 2025	Nov 24, 2025	-$0.54	$0.00	+100.00%(+$0.54)
Q2 2025	Aug 14, 2025	-$0.53	$0.00	+100.00%(+$0.53)

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
BLRXBioLineRX Ltd	B	F	C	$2.60
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About BioLineRX Ltd

BioLine Rx is a commercial-stage biopharmaceutical company developing oncology-focused therapies. The company's pipeline includes two clinical-stage candidates: motixafortide (BL-8040), a peptide targeting stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent for solid tumors. The company also maintains a legacy product, BL-5010, for skin lesions, and has generated revenue through milestone payments and out-licensing agreements.